RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Christopher Navara to Antineoplastic Agents

This is a "connection" page, showing publications Christopher Navara has written about Antineoplastic Agents.
Connection Strength

0.331
  1. Navara CS, Benyumov A, Vassilev A, Narla RK, Ghosh P, Uckun FM. Vanadocenes as potent anti-proliferative agents disrupting mitotic spindle formation in cancer cells. Anticancer Drugs. 2001 Apr; 12(4):369-76.
    View in: PubMed
    Score: 0.113
  2. Uckun FM, Mao C, Jan ST, Huang H, Vassilev AO, Navara CS, Narla RK. Spongistatins as tubulin targeting agents. Curr Pharm Des. 2001 Sep; 7(13):1291-6.
    View in: PubMed
    Score: 0.029
  3. Uckun FM, Sudbeck EA, Mao C, Ghosh S, Liu XP, Vassilev AO, Navara CS, Narla RK. Structure-based design of novel anticancer agents. Curr Cancer Drug Targets. 2001 May; 1(1):59-71.
    View in: PubMed
    Score: 0.029
  4. Ghosh P, Ghosh S, Navara C, Narla RK, Benyumov A, Uckun FM. X-ray structure, solution properties, and biological activity profile of vanadocene(IV) acetylacetonate complex,. J Inorg Biochem. 2001 Apr; 84(3-4):241-53.
    View in: PubMed
    Score: 0.028
  5. Uckun FM, Mao C, Jan ST, Huang H, Vassilev AO, Sudbeck EA, Navara CS, Narla RK. SPIKET and COBRA compounds as novel tubulin modulators with potent anticancer activity. Curr Opin Investig Drugs. 2000 Oct; 1(2):252-6.
    View in: PubMed
    Score: 0.027
  6. Jan ST, Mao C, Vassilev AO, Navara CS, Uckun FM. COBRA-1, a rationally-designed epoxy-THF containing compound with potent tubulin depolymerizing activity as a novel anticancer agent. Bioorg Med Chem Lett. 2000 Jun 05; 10(11):1193-7.
    View in: PubMed
    Score: 0.027
  7. Uckun FM, Mao C, Vassilev AO, Navara CS, Narla RK, Jan ST. A rationally designed anticancer drug targeting a unique binding cavity of tubulin. Bioorg Med Chem Lett. 2000 May 15; 10(10):1015-8.
    View in: PubMed
    Score: 0.027
  8. Narla RK, Dong Y, D'Cruz OJ, Navara C, Uckun FM. Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) as a novel apoptosis-inducing anticancer agent. Clin Cancer Res. 2000 Apr; 6(4):1546-56.
    View in: PubMed
    Score: 0.026
  9. Ghosh S, Zheng Y, Jun X, Narla RK, Mahajan S, Navara C, Mao C, Sudbeck EA, Uckun FM. Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. Clin Cancer Res. 1998 Nov; 4(11):2657-68.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support